UnitedHealth Ebitda vs Total Other Income Expense Net Analysis
| UNH Stock | USD 590.87 6.62 1.11% |
UnitedHealth Group financial indicator trend analysis is much more than just breaking down UnitedHealth Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UnitedHealth Group is a good investment. Please check the relationship between UnitedHealth Group Ebitda and its Total Other Income Expense Net accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UnitedHealth Group Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Ebitda vs Total Other Income Expense Net
Ebitda vs Total Other Income Expense Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UnitedHealth Group Ebitda account and Total Other Income Expense Net. At this time, the significance of the direction appears to have pay attention.
The correlation between UnitedHealth Group's Ebitda and Total Other Income Expense Net is -0.84. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of UnitedHealth Group Incorporated, assuming nothing else is changed. The correlation between historical values of UnitedHealth Group's Ebitda and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of UnitedHealth Group Incorporated are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Ebitda i.e., UnitedHealth Group's Ebitda and Total Other Income Expense Net go up and down completely randomly.
Correlation Coefficient | -0.84 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Ebitda
Total Other Income Expense Net
Most indicators from UnitedHealth Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UnitedHealth Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UnitedHealth Group Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. As of now, UnitedHealth Group's Selling General Administrative is increasing as compared to previous years. The UnitedHealth Group's current Enterprise Value is estimated to increase to about 500.3 B, while Tax Provision is projected to decrease to under 5 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 285.3B | 322.1B | 371.6B | 390.2B | Depreciation And Amortization | 3.1B | 3.4B | 4.0B | 4.2B |
UnitedHealth Group fundamental ratios Correlations
Click cells to compare fundamentals
UnitedHealth Group Account Relationship Matchups
High Positive Relationship
High Negative Relationship
UnitedHealth Group fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 173.9B | 197.3B | 212.2B | 245.7B | 278.4B | 292.3B | |
| Total Current Liabilities | 61.8B | 72.4B | 78.3B | 89.2B | 99.1B | 104.0B | |
| Total Stockholder Equity | 60.4B | 65.5B | 71.8B | 77.8B | 88.8B | 93.2B | |
| Property Plant And Equipment Net | 8.7B | 8.6B | 9.0B | 10.1B | 11.5B | 12.0B | |
| Net Debt | 29.7B | 26.5B | 24.6B | 34.3B | 42.0B | 44.1B | |
| Retained Earnings | 61.2B | 69.3B | 77.1B | 86.2B | 95.8B | 100.6B | |
| Cash | 11.0B | 16.9B | 21.4B | 23.4B | 25.4B | 26.7B | |
| Non Current Assets Total | 131.3B | 143.6B | 150.4B | 176.6B | 200.0B | 210.0B | |
| Non Currrent Assets Other | 94.0B | 102.3B | 107.3B | 12.3B | 69.6B | 73.1B | |
| Cash And Short Term Investments | 14.2B | 19.8B | 23.9B | 27.9B | 29.6B | 31.1B | |
| Net Receivables | 11.8B | 25.4B | 28.1B | 30.5B | 39.0B | 40.9B | |
| Common Stock Shares Outstanding | 966M | 961M | 956M | 950M | 938M | 1.2B | |
| Liabilities And Stockholders Equity | 173.9B | 197.3B | 212.2B | 245.7B | 273.7B | 287.4B | |
| Non Current Liabilities Total | 49.9B | 54.3B | 57.4B | 70.1B | 80.4B | 84.5B | |
| Other Current Assets | 16.6B | 8.5B | 9.8B | 10.7B | 9.8B | 6.2B | |
| Other Stockholder Equity | 16M | 2.8B | 3.3B | 3.7B | 4.2B | 4.4B | |
| Total Liab | 111.7B | 126.8B | 135.7B | 159.4B | 179.5B | 188.5B | |
| Total Current Assets | 42.6B | 53.7B | 61.8B | 69.1B | 78.4B | 82.4B | |
| Short Long Term Debt Total | 40.7B | 43.5B | 46.0B | 57.6B | 67.4B | 70.8B | |
| Intangible Assets | 10.3B | 10.9B | 10.0B | 14.4B | 15.2B | 16.0B | |
| Other Current Liab | 33.6B | 20.4B | 23.0B | 26.3B | 58.4B | 61.4B | |
| Short Term Debt | 3.9B | 4.8B | 3.6B | 3.1B | 5.3B | 5.6B | |
| Accounts Payable | 21.7B | 44.4B | 49.1B | 56.8B | 32.0B | 33.6B | |
| Short Term Investments | 3.3B | 2.9B | 2.5B | 4.5B | 4.2B | 4.4B | |
| Accumulated Other Comprehensive Income | (3.6B) | (3.8B) | (5.4B) | (8.4B) | (7.0B) | (6.7B) | |
| Good Will | 65.7B | 71.3B | 75.8B | 93.4B | 103.7B | 108.9B | |
| Property Plant And Equipment Gross | 8.7B | 8.6B | 15.0B | 17.1B | 18.5B | 19.4B | |
| Other Liab | 10.0B | 15.7B | 15.1B | 11.8B | 13.5B | 14.2B | |
| Other Assets | 13.8B | 52.8B | 107.3B | 20.7B | 23.8B | 13.1B | |
| Long Term Debt | 36.8B | 38.6B | 42.4B | 54.5B | 58.3B | 61.2B | |
| Property Plant Equipment | 8.7B | 8.6B | 9.0B | 10.1B | 11.6B | 12.2B | |
| Current Deferred Revenue | 2.6B | 2.8B | 2.6B | 3.1B | 3.4B | 2.5B | |
| Net Tangible Assets | (16.7B) | (14.5B) | 75.0B | (25.1B) | (28.8B) | (27.4B) | |
| Noncontrolling Interest In Consolidated Entity | 2.8B | 2.8B | 3.3B | 3.7B | 4.2B | 4.4B | |
| Retained Earnings Total Equity | 61.2B | 69.3B | 77.1B | 86.2B | 99.1B | 51.1B | |
| Long Term Debt Total | 36.8B | 38.6B | 42.4B | 54.5B | 62.7B | 65.8B |
Currently Active Assets on Macroaxis
When determining whether UnitedHealth Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UnitedHealth Group's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Unitedhealth Group Incorporated Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Unitedhealth Group Incorporated Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UnitedHealth Group Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UnitedHealth Group. If investors know UnitedHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UnitedHealth Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.043 | Dividend Share 7.96 | Earnings Share 15.36 | Revenue Per Share 427.221 | Quarterly Revenue Growth 0.092 |
The market value of UnitedHealth Group is measured differently than its book value, which is the value of UnitedHealth that is recorded on the company's balance sheet. Investors also form their own opinion of UnitedHealth Group's value that differs from its market value or its book value, called intrinsic value, which is UnitedHealth Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UnitedHealth Group's market value can be influenced by many factors that don't directly affect UnitedHealth Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UnitedHealth Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if UnitedHealth Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UnitedHealth Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.